Skip to main content
Premium Trial:

Request an Annual Quote

Cynvenio, St. Luke's Partner on Breast Cancer Study

NEW YORK (GenomeWeb) – Cynvenio Biosystems today announced the launch of a breast cancer monitoring study in partnership with Saint Luke's Cancer Institute.

The goal of the study — which is directed at patients at high risk of relapse after neoadjuvant chemotherapy — is to evaluate the use of liquid biopsy and natural killer cell testing for the early detection of recurrent breast cancer. In the first phase, patients who are scheduled for neoadjuvant chemotherapy before surgery will get tested. In the next phase, patients will be tested after surgery.

Cynvenio offers the ClearID Breast Cancer test, which sequences 27 genes commonly mutated in breast cancer. The test analyzes cell-free DNA and circulating tumor cells before and after treatment, while assessing the correlation of natural killer cell activity to a patient's response to chemotherapy. The firm said that the study is anticipated to determine whether the surveillance of CTC and NK cells are predictive of clinical relapse following neoadjuvant therapy. 

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.